Welcome to Building Design+Construction’s third Multifamily Annual Report. Every year since 2023, the editors of BD+C have consulted with dozens of leading multifamily design and construction firms, ...
Design Therapeutics, Inc. announced the initiation of a Phase 1 clinical trial for its gene-targeted treatment DT-216P2 in healthy volunteers, with patient dosing for Friedreich Ataxia (FA) set to ...
To supplement amounts presented in our consolidated financial statements determined in accordance with accounting principles generally accepted in the U.S. ("GAAP"), the Company uses certain non-GAAP ...
Nearly 6,000 global industry leaders, futurists, and experts across Design and Make industries share insights and solutions in third annual survey "The accelerating pace of innovation and demand for ...
Financial reporting requires accuracy, consistency, and compliance with accounting standards. Businesses must collect ...
To supplement amounts presented in our consolidated financial statements determined in accordance with accounting principles generally accepted in the U.S. ("GAAP"), the Company uses certain non-GAAP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results